Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Fair enough HT. Let's wait and see shall we.
Ssccss..but your opinion has no basis other than being a troll....Its so transparent it's hilarious
Thanks for the extracts Hulver. Be nice if HEMO had a bit more in the kitty but the report makes the situation clear
Keep it up folks; must be getting close to a new world record on here today.
https://www.youtube.com/watch?v=USh-hM_Nq4Q
If you stopped acting like we are in a playground but actually listened to alternative opinions, you might actually make some money.
Hemotruth you are really good at picking up half a story. I have bought and sold hemo since. I don't post all my activities. Honestly your powers of deduction need some work.
Exactly HT -
Company published results & Proactive investors are an investment organisation that highlight possible investments
& there current status etc etc & Vlad is at the spearhead of a science company doing great work & agreed to the interview to project Hemo & a potential investment & Proactive print the interview & facts - simple as they do with many companies every month .
Shorts / stock on loan
( which I only post to assist the invested for info purposes )
4.2 million opened @around 1.6 after the placement will be paying the cost to borrow daily so 6 weeks in , likely on a loss & sweating if a positive RNS drops .
The impatient sell & the small time Shorters try & fleece a few quid ,
However imo the investors with patience will be rewarded & Prevail certainly saw the potential otherwise why invest & get involved …
Noted by Prevail in Sept RNS
Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."
Let’s see what next few months bring
And the Auditor's Assessment of the Board's views on going concern and teh next 18+ months:
P42: "Key Audit Matter: Going concern (Group and parent company – Note 2)
As part of our audit, we have performed the following procedures:
• Reviewed management’s assessment of going concern to 31 December 2025 and assessed the reasonableness of key assumptions and inputs used by management;
• Evaluated and corroborated the key assumptions and inputs underlying the budgets and cash flow forecasts, including sensitivity analysis against the base case scenario;
• Discussed with management how they intend to fund the clinical trials and other clinical programs, including an assessment of the funding options currently under negotiation;
• Compared management’s forecasts to actual results through the subsequent events period and performed inquiries to the date of this report;
• Assessed the probability of obtaining additional sources of funds when required, together with the ability to defer research and development expenditure; and
• Assessed the disclosures made regarding going concern in the financial statements for consistency with management’s assessment.
The group intends to progress its key development project to clinical trials together with the performance of other clinical programs. Significant additional funds will be required in order to progress as planned, which are not yet agreed and unconditional. As disclosed in Note 2, the group has a high proportion of discretionary expenditure which it is able to defer, if sufficient funding is not available. "
And just to emphasise some key words above:
"including an assessment of the funding options currently under negotiation."
Funding matters are being 'negotiated'. This to me still suggests Prevail led PIPE funding round.
From the Annual Report - the Company's view of the next 12 - 18 months:
"The Company successfully raised £5.25 million (before expenses) through the allotment and issue of new ordinary shares during the year ended 31 December 2023, and a further £3.25 million in early 2024. These proceeds were raised in order to facilitate the progression of the Company's HEMO- CAR-T product candidate into clinical trials and to enable the Company to continue development of product candidates for the treatment of viral infections and cancers based on its CBR platform.
Funding will be required by the Company to complete Phase I clinical development.
The Company cannot be certain that such additional funding will be available on acceptable terms, or at all. To the extent that the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience dilution. Any debt financing, if available, may involve restrictive covenants. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to (i) significantly delay, scale back or discontinue the development and/or commercialisation of one or more product candidates; (ii) seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favourable than might otherwise be available; or (iii) relinquish or otherwise dispose of rights to technologies, product candidates or products that it would otherwise seek to develop or commercialise on unfavourable terms.
However, the Directors are of the opinion that the Company has adequate working capital to execute its operations for the present time and is confident in its ability to access additional financing over the next 12 months. The Directors, therefore, have made an informed judgement, at the time of approving these financial statements, that there is a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. As a result, the Directors have continued to adopt the going concern basis of accounting in preparing the annual financial statements. "
And on P27: Carrying value of investment in Hemogenyx Pharmaceuticals LLC
"The Committee reviewed the impairment assessment report prepared by management and agreed that given the reasonable expectation that the Group will achieve its milestone targets over the next 18 months no impairment to the value of the investment in Hemogenyx Pharmaceuticals LLC was required as at 31 December 2023."
He did the interview as the year end results had just been published...are you stupid as that's the second time you have asked that question, I see you sold hemo at 1.22p so your motive is clear.
At present the amount of shorts is F--k all MM can move this 5/10% at will and make there money because they can see who has stop losses or will be on margin call. This is not for the faint hearted
A 4.2 million short @ 1.62 not underwater now
There's also the question of why Vlad did the recent interview... Maybe to help lift the sp... But for what reason? Not so traders could sell into it...
I think it's probably related to the fact the trial will take a long time and a raise will need to be made soon. So no there isn't much opportunity for news to lift the sp before a raise, so it will probably need to be at a discount IMO.
Seriously, £143.81k sells today.
Someone convince me this isn't symptomatic of something potentially very horrible on its way.
No, I'm not deramping or some sh*t like that. I'm an anxious LTH who would like to at least get his money back...!
Yup. some get bored I guess. Only 11m volume. You either believe trials will show positive results before year end or you dont. 52week range 1.1-7.13 so we know where this can go with a bit of positivity. GL holders
Cog got jammed today, why would anyone sell at these levels.
The sp ALWAYS returns back to the placing price. It’s just a matter of when. All those that sold today, did at a loss, which is a shame
Wondering why you've decided to post this now?
When its time to get out, its time to get out !!
No news, loose cannon (company wise) at the helm, low funds, many competitors for funding and a share that is well on the shorters radar, as we have seen an easy target.. take your pick.
At this point, no use in worrying MrI.. purely resting on a successful trial to have any hope
Haywain,
Thank you for the response.
It appears fair and unbiased , although with a positive slant as you openly admit.
More of the same might benefit this board.
AIMO
DYOR
I'm not going to live long enough for this bird to fly
Hello All
This stock on Ind approval was 7p. It was hovering around 4p prior to IND approval. We didnt have funding for trials and news on CBR. This stock is now 1.6p and no interest.
Is it people waiting for trials to start to invest?
is it people find hemo too risky to invest?
Are people so risk adverse that they see better investments out there?
Do people believe that this CART is inferior to other CART drugs out there?
I am confused at the UK stock market and how a pre-clinical CART company is around £20m MCAP and it is struggling to get momentum. Is it being suppressed or is there generally no interest in investing in junior pharma.
I am confused by the lack of interest in hemo even after multiple proactive investor updates. Opinions?
@Cyrox
I agree in your assessment.
And that is also why I consider investing in a pure research company high risk.
There is always the risk of failure.
And if there is no income then it often means that the company will have to go back to the market and ask for more funds.
And often at a lower share price, because usually, negative news will have that effect on the share price.
But I think we're lucky with what we got.
Product line wise
Scientist wise
BOD wise
Investor wise (particularly shout-out to Prevail)
Humanized mice wise.
All of these things makes me confident in my investment.
I think the risk of Patient 1, ballooning up like an elephant is small.
We have been told that as a clinical company there are funding available to us that were not there before and that the BOD is looking into various avenues to ensure we won't have to raise at this level again.
So if we are lucky, we'll get some non dilutive money from somewhere and it will have a positive boost to the share price. (But I'm not holding my breath on that one)
If we are even luckier, then Patient 1, will be jumping out of bed 3 days later, participate in the first upcoming marathon and win in record time, despite having been bed bound for the previous 6 month and incured significant muscle loss as a consequence.
Then, and only then do I dare to believe that there will be a run on shares in Hemogenyx.
Because let's face it, there should already be a run on the company's shares with everything that has happened in the last couple of years.
So you're right, a lot depends on the outcome of Patient 1.
But that is always the case.